The cardioselective beta1-adrenergic receptor antagonist, bisoprolol, inhibits isoprenaline-induced relaxation of human chorionic plate arteries

Physiology in Focus 2024 (Northumbria University, UK) (2024) Proc Physiol Soc 59, PCB017

Poster Communications: The cardioselective beta1-adrenergic receptor antagonist, bisoprolol, inhibits isoprenaline-induced relaxation of human chorionic plate arteries

Teresa Tropea1, Paul Brownbill1, Anthony M. Heagerty1, Jenny E. Myers1,

1Maternal & Fetal Health Research Centre, University of Manchester Manchester United Kingdom, 2St Mary's Hospital, Manchester University Hospital NHS Foundation Trust Manchester United Kingdom, 3Division of Cardiovascular Sciences, University of Manchester Manchester United Kingdom,

View other abstracts by:


Introduction: The placenta is a low-resistance vascular organ that provides an efficient maternal-fetal exchange system for oxygen and nutrients. The cardioselective beta1-adrenergic receptor antagonist, bisoprolol, is commonly prescribed to women with pre-existing cardiac disease to improve maternal stroke volume and cardiac output during pregnancy. Clinical evidence of decreased umbilical blood flow velocity and increased rate of low-birth-weight babies in women exposed to bisoprolol [1] raises safety concerns. Although the placenta is devoid of innervation, we hypothesised that bisoprolol may alter placental perfusion via a direct effect on beta-adrenergic receptors in isolated human placental chorionic plate arteries (CPAs).

Methods: CPAs (<500µm diameter) were dissected from biopsies of uncomplicated term placentas (N=3-5). Using wire myography, concentration-dependent effects of the non-selective beta-adrenergic receptor agonist isoprenaline (10-9-10-5M) were tested on CPAs pre-incubated with bisoprolol (10-5M and 10-4M) and pre-constricted with an EC80 dose of U-46619. Sensitivity was evaluated as the molar concentration of isoprenaline causing 50% of the maximal effect (Emax) and expressed as logarithm. 

Results: Isoprenaline caused significant relaxation of CPAs in a dose-dependent manner (P<0.0001. Figure 1A). The relaxant effect of isoprenaline was significantly reduced after pre-incubation with bisoprolol 10-5M (P<0.05. Figure 1B) and was abolished by blockade with bisoprolol 10-4M (P<0.0001. Figure 1B). Maximum relaxation to isoprenaline was significantly reduced by bisoprolol 10-4M (Emax, P<0.01; 24.01 ± 6.09 vs 5.21 ± 6.94%. Figure 1C), whereas the sensitivity was not different between the two groups (P=0.800, -7.178 ± 0.56 vs -8.316 ± 1.53 LogEC50; isoprenaline vs isoprenaline + bisoprolol 10-4M).

Conclusions: These data show non-selective functional activation and inhibition of beta-adrenergic receptors on CPAs. The increased inhibitory effect of bisoprolol at supraphysiological concentration (10-4M) tested on isoprenaline-induced relaxation may suggest potential off target beta1 blockade effects. Further study is needed to determine the functional role of beta-adrenergic receptors on the fetoplacental vasculature and to identify the relationship between actions mediated by maternal plasma levels of bisoprolol on CPAs and placental perfusion.



Where applicable, experiments conform with Society ethical requirements.

Site search

Filter

Content Type